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INTRODUCTION
Various intestinal symptoms or diseases such as
diarrhea, constipation, abdominal pain and mixed
irritable bowel syndrome are closely associated
with several pathophysiological conditions includ-
ing stress conditions and diabetes (1, 2). The psy-
chological or neuronal disturbances associated with
these diseases are considered to be involved in the
etiology of these intestinal symptoms (3, 4). Simi-
larly, metabolic disorders such as obesity have also
been reported to be associated closely with these in-
testinal symptoms (5-7), with increased body mass
index correlating with the incidence of diarrhea and
abdominal pain in humans (6, 7). Although the pre-
cise mechanisms responsible for these intestinal
symptoms remain unclear, it is possible abnormal
contraction of intestinal smooth muscle cells may be
involved in the development of the conditions (8-10).
In this regard, Dai, et al . (8) reported that colon
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ring strips from rats subjected to cold restraint stress
had a higher contractile response to acetylcholine
(ACh) compared with non-stressed control animals.
ACh receptor-mediated hypercontractility was also
observed in intestinal strips of rats with type I dia-
betes (11). In addition, it has been suggested that
the contractile activity of both small and large in-
testines may be disturbed in obese subjects (12). It
is therefore important that drugs used in the treat-
ment of metabolic disorders such as obesity or dia-
betes should not have any adverse effects on gas-
trointestinal symptoms. Despite this requirement
there have been only a small number of research
reports describing the effect of these drugs on gas-
trointestinal symptoms.
The chemical compound [4-(4-bromo-2-cyano-
phenylcarbamoyl)-benzyl]-phosphonic acid diethyl
ester (NO-1886) is a lipoprotein lipase activator dis-
covered by the Otsuka Pharmaceutical Factory, Inc.
(13). Administration of NO-1886 was shown to in-
crease plasma HDL-cholesterol levels and decrease
triacylglycerol levels in both the plasma and liver
of streptozotocin-induced diabetic rats fed a high
fat diet (14). NO-1886 was also shown to suppress
fat accumulation and improve insulin resistance in
rats fed a high-fat diet (15) and miniature pigs fed
a high-fat/high-sucrose-diet (16). While the molecu-
lar and intracellular details of the mechanisms re-
sponsible for these improvements remain unclear,
NO-1886 represents a new candidate drug for the
treatment of dyslipidemia or diabetic conditions as-
sociated with obesity.
Recently we demonstrated NO-1886 inhibited ex-
tracellular Ca2+- and intracellular myosin light chain
kinase (MLCK)-dependent contractions of rat aor-
tic smooth muscle (17). This finding implies that
NO-1886 may be useful for treating cardiovascular
dysfunction associated with increased blood vessel
contractility (17). As extracellular Ca2+ and MLCK
also participate in controlling gastrointestinal smooth
muscle contractility (18, 19), we hypothesize that
NO-1886 may cause an attenuation of this contrac-
tile response. In this paper we show that NO-1886
has an inhibitory effect on stimulant-induced intes-
tinal contractions.
MATERIALS AND METHODS
Agents
Agent NO-1886 was synthesized in the New Drug
Research Laboratory of Otsuka Pharmaceutical
Factory Inc., Tokushima, Japan. N-(6-Aminohexyl)-
5 -chloro-1-naphthalenesulfonamide hydrochlo-
ride (W7), and (S)-(+)-2-Methyl-1-[(4-methyl-5-
isoquinolinyl)sulfonyl]homopiperazine dihydro-
chloride (H-1152) were purchased from Calbio-
chem (San Diego, CA, USA). Staurosporine was
purchased from Wako Pure Chemical Industries
(Osaka, Japan) and 1-(5-Chloronaphthalene-1-
sulfonyl)homopiperazine hydrochloride (ML-9)
from Biomol International, L.P. (Exeter, UK). NO-
1886, staurosporine and ML-9 were dissolved in
dimethyl sulfoxide (DMSO), while W7 and H-1152
were dissolved in distilled water.
Animals
Male Wistar rats aged 6 weeks were purchased
from Japan SLC, Shizuoka, Japan. Spontaneous type
2 diabetic OLETF (Otsuka Long-Evans Tokushima
Fatty) rats and their counterpart control, the LETO
(Long-Evans Tokushima Otsuka) rats, aged 4 weeks,
were supplied by the Tokushima Research Institute,
Otsuka Pharmaceutical, Tokushima, Japan. The rats
were housed singly at a constant room tempera-
ture of 23 1with a 12-hour light/dark cycle,
and were fed a standard non-purified diet (Oriental
Yeast, Tokyo, Japan) with food and water available
ad libitum. Male Wistar rats aged between 7-9 weeks
and OLETF/LETO rats aged 17 weeks were used
for the experiments. All animal procedures were in
accordance with the institutional guidelines for the
care and use of laboratory animals of The Univer-
sity of Tokushima.
Metabolic disturbances in the OLETF rats were
confirmed by measuring bodyweight, blood glu-
cose levels during the fasting and fed states, blood
lipids (triglyceride and total cholesterol), and by
an oral glucose tolerance test (OGTT) (20). For the
measurement of blood chemicals, the rats were anes-
thetized by an intraperitoneal injection of pentobar-
bital (50 mg/kg). Blood samples were collected
from the jugular vein. The plasma concentrations
of triglyceride and total cholesterol were measured
using commercial kits according to the manufac-
turer’s protocols (Wako, Osaka, Japan). The meth-
ods are based on the reaction cascade where a tri-
glyceride or a cholesterol produces hydrogen per-
oxide that yields a blue colored complex upon oxi-
dative condensation of 4-aminoantipyrine with 3,5-
dimethoxy-N-ethyl-N-(2’ -hydroxy-3’ -sulfopropyl) -
anilinenatrium in the presence of peroxidase. Mes-
enteric, epididymal, and retroperitoneal fat samples
were collected, weighed and compared with sam-
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ples obtained from non-diabetic LETO rats.
Preparation of intestinal rings and tension meas-
urements
The rats were fasted for 24 hours and then anes-
thetized by an intraperitoneal injection of pento-
barbital (50 mg/kg). The intestines were removed
and dissected free of connective tissue and then
cut into ring segments, 3- to 4-mm in length. Each
ring was then placed in a 3 ml organ bath (Micro
Easy Magnus, Kishimoto Medical ; Kyoto, Japan)
and mounted on two stainless steel wires, one of
which was fastened to the bath, while the other was
connected to a force transducer that measured iso-
metric tension. The bath was filled with Krebs-
Ringer bicarbonate buffer (KRB) solution at 37
and bubbled with a mixture of 95% O2-5% CO2. The
KRB contained (in mmol/l) 118 NaCl, 4.6 KCl, 2.5
CaCl2, 24.8 NaHCO3, 1.2 MgSO4, 1.2 KH2PO4, and
5.6 glucose. The rings were equilibrated for 60 min
under a resting tension of 1.0 g, with the solution
being changed at 30 min intervals. The intestinal
rings were then contracted by a high K+ concen-
tration solution (50 mM KCl in bath solution). Af-
ter recording the contractile force of each ring fol-
lowing stimulation with 50 mM KCl, the baths were
washed out with KRB. Each ring was allowed to
equilibrate at a resting tension of 1.0 g for 20 min.
The contractile responses measured under the fol-
lowing test conditions were expressed relative to
those measured in the 50 mM KCl-induced con-
traction (1st KCl) (21).
Studies on the effect of NO-1886
Test experiments involving NO-1886 were con-
ducted on intestinal rings in which contraction was
induced by either KCl (0, 30, 50, or 80 mM) or ACh
(100 μM). The concentrations of NO-1886 used
were 1, 3 and 10 μM. NO-1886 was added to the in-
cubation system either 20 min prior to or during the
contraction induced by each constrictor. Vehicle
(DMSO)-treated rings were used as controls. In
some experiments, intestinal contraction was per-
formed in the absence of extracellular Ca2+ using
Ca2+-free KRB containing 1 mM EGTA.
Inhibitor experiments
Several inhibitors were used to examine the role
of intracellular signaling pathways in the action of
NO-1886. The concentrations of inhibitors used in
this study were as follows : staurosporine [protein
kinase C (PKC) inhibitor ; 100 nM], H-1152 [Rho
kinase (ROK) inhibitor ; 100 nM], W7 (calmodulin
inhibitor ; 100 μM), and ML-9 [myosin light chain
kinase (MLCK) inhibitor ; 30 μM]. The intestinal
rings were pre-treated with each inhibitor for 20
min and then contraction was induced by KCl (50
mM) or ACh (100 μM). Each inhibitor was present
in the incubation system during contraction.
Western blot analysis
The colon was isolated from OLETF or LETO
rats (each n=4) and dissected free of connective
tissue and then cut into ring segments, 3- to 4-mm
in length. Tissue protein extracts were prepared
by homogenizing tissues in a radio immune pre-
cipitation assay (RIPA) buffer containing 20 mM
tris (hydroxymethyl) aminomethane-hydrogen
chloride (Tris-HCl) (pH7.4), 150 mM NaCl, 1% so-
dium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), 1% octylphenolpoly (ethyleneglycolether)
(Nonidet-P40), 2 mM ethylenediamine tetraacetic
acid (EDTA), and 1 mM phenylmethyl sulfonyl fluo-
ride (PMSF) for 30 min on ice. The tissues were
then passed through a 21-gauge needle followed by
centrifugation at 13,500 x g for 30 min at 4. The
supernatant was used as a protein sample of the tis-
sue extracts. Protein concentration was measured
by the bicinchoninic acid (BCA)TM protein assay kit
(Pierce, Rockford, IL). This method is based on the
reactions where the proteins reduce Cu+2 to the cu-
prous cation (Cu+1) that reacts with BCA to form
purple colored product.
A 50 μg aliquot of protein was denatured by boil-
ing for 2 min in loading buffer [4% SDS, 250 mM
Tris-HCl, pH 6.8, 1% β-mercaptoethanol, 1% bromo-
phenol blue, and 20% glycerol]. The proteins were
subjected to SDS-polyacrylamide gel electrophore-
sis and transferred onto Immobilon-P membranes
(Millipore, Bedford, MA, USA). The membranes
were blocked for 1 hour using 5% skim milk in Tris-
buffered saline (TBS) containing 0.05% polysorbate
20 (Tween 20, which was added to the blocking
buffer to prevent nonspecific binding). Then mem-
branes were incubated with either an anti-myosin
light chain (MLC) rabbit polyclonal antibody (1 :
1000, Cell Signaling Technology, Inc., MA, USA) or
anti-muscarinic M3 ACh receptor (ACh-M3R) rab-
bit polyclonal antibody (Santa Cruz Biotechnology,
Inc, CA, USA). Visualization of the attached anti-
bodies was carried out using goat anti-rabbit IgG
horseradish peroxidase conjugate secondary anti-
body (1 : 2000, Biosource International, Camarillo,
CA) using an ECL Plus detection kit (Amersham
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Pharmacia Biotech, Aylesbury, UK).
Statistical analysis
Data are expressed as the meanSD. Data were
analyzed by analysis of variance and Bonferroni mul-
tiple comparison tests. Student’s t-test was used for
paired data when appropriate. A P value 0.05 was
considered to be statistically significant.
RESULTS
NO-1886 attenuates KCl-induced contraction in rat
intestines
The effect of NO-1886 on intestinal contraction in-
duced by KCl was examined initially using rat il-
eum ring preparations. Administration of NO-1886 to
ring preparations under basal conditions did not alter
basal tone (data not shown). As shown in Fig. 1A,
pretreatment with NO-1886 (10 μM) attenuated sub-
sequent KCl (30-80 mM)-induced maximum con-
traction of rat ileum. As shown in Fig. 1B, admini-
stration of NO-1886 during KCl (50 mM)-induced
contraction caused a dose-dependent relaxation in
ileal tensions. The maximum relaxing effect for
NO-1886 was observed at a concentration of 10 μM.
The effect of NO-1886 at concentrations more than
10 μMwas not determined as the drug did not dis-
solve completely in the incubation buffer at these
high concentrations. The relaxing effects of NO-1886
on KCl (50 mM)-induced contraction were also ob-
served for other intestinal preparations including
colon and the rectum (Fig. 1C).
The relaxing effect of NO-1886 did not occur in the
absence of extracellular Ca2+
Our previous study demonstrated that NO-1886
inhibition of KCl-induced vasocontraction of rat
aortic rings was mediated by an extracellular Ca2+-
dependent mechanism (17). To examine the involve-
ment of extracellular Ca2+ in the relaxing effect of
NO-1886 on intestinal contraction, ileal ring prepa-
rations were exposed for 20 min to Ca2+-free KRB
containing 1 mM EGTA. Removal of extracellu-
lar Ca2+ largely attenuated the subsequent KCl
(50 mM)-induced contraction (% attenuation : 64.6
15.2%). Under these conditions, NO-1886 did not
cause relaxation (Fig. 2A). This finding indicated
NO-1886-induced inhibition of ileal contraction was
dependent on extracellular Ca2+.
Effect of inhibitors of signaling molecules on NO-
1886-induced ileal relaxation
A rise in intracellular calcium results in the forma-
tion of a Ca2+/calmodulin complex, leading to sub-
sequent activation of MLCK, MLC phosphorylation,
and finally smooth muscle contraction (19, 22). Ad-
ditional signaling pathways involving ROK and PKC
increase myofilament force sensitivity to [Ca2+]i,
thereby maintaining vascular contraction (19, 22,
23). NO-1886-induced inhibition of vasocontraction
of rat aortic rings has been shown to involve MLCK,
but not PKC, calmodulin nor ROK (17). In the pre-
sent study, the effects of inhibitors of these signal-
ing molecules were examined in ileal ring prepara-
tions in the presence or absence of NO-1886. Pre-
treatment with either staurosporine (PKC inhibi-
tor), H-1152 (ROK inhibitor), W7 (calmodulin in-
hibitor) or ML-9 (MLCK inhibitor) attenuated KCl-
induced contractions [% inhibition ; staurosporine
(39.6  3.2%), H-1152 (32.2  6.7%), W7 (36.5 
11.2%), and ML-9 (72.63.2%)]. As shown in Fig.
2B, neither staurosporine, H-1152 nor W7 influ-
enced the relaxing effect of NO-1886 during KCl-
A B C
Fig. 1 NO-1886 attenuated KCl-induced contraction in Wistar rat intestines. (A) NO-1886 pretreatment (10 μM for 20 min) attenu-
ated subsequent KCl-induced contraction in rat ileum ring preparations. Vehicle (DMSO) treatment was used as the control. (B)
NO-1886 caused a dose-dependent relaxation in the ileal rings which had been contracted by KCl (50 mM). (C) NO-1886 (10 μM)
induced the maximum relaxation response in the ileum, colon and rectum ring preparations. Each contractile value in (A) was
standardized against the contraction level induced by 50 mM KCl in the absence of pretreatment (1st KCl). Data are expressed as
meansSD for 4-8 intestinal rings in each group. *P0.05 and P0.01, compared with vehicle group.
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induced contraction. In contrast, pre-treatment with
ML-9, an MLCK inhibitor, completely blocked the
relaxing effect of NO-1886 on KCl-induced ileal con-
traction (Fig. 2B).
NO-1886 attenuates ACh-induced intestinal con-
traction via an MLCK-dependent pathway
ACh is one of the most important neurotrans-
mitters in the intestine, where ACh released from
the enteric nervous system mediates gastrointesti-
nal tract contractions (24). ACh binds to its recep-
tor, (i.e. the muscarinic ACh receptors including
ACh-M3R) (25), and increases intracellular Ca2+
levels and binding to calmodulin, which in turn in-
duces smooth muscle contraction via activation of
MLCK (19, 22). Fig. 3 summarizes the effect of
NO-1886 on ACh (100 μM)-induced contraction in
colon and rectum ring preparations. In our prelimi-
nary experiments, ACh (100 μM) did not induce
contraction in the ileal ring preparations (data not
shown). As ACh-stimulated rings were unable to sus-
tain their plateau contractile level (data not shown),
the maximum contractile levels were used in the
data analyses. As shown in Fig. 3, pretreatment with
NO-1886 significantly attenuated ACh-stimulated
contraction in both colon and rectum preparations.
Pretreatment with W7 and ML-9 alone also inhib-
ited the development of subsequent ACh-induced
contraction (open bars in Fig. 3). NO-1886 showed
an inhibitory effect on ACh-stimulated contraction
even in the presence of W7, although this effect dis-
appeared when the rings were pre-incubated with
ML-9 (Fig. 3). These data suggest that NO-1886 at-
tenuated ACh-induced intestinal contraction via the
MLCK-dependent pathway.
A B
Fig. 2 (A)The effect of removing extracellular Ca2+ on NO-1886-induced relaxation in ileal ring preparations. (B) Effects of several
inhibitors of signaling molecules on the relaxing effect of NO-1886. The inhibitors used were W 7 (100 μM), Staurosporine (STA,
100 nM), H-1152 (100 nM), and ML-9 (30 μM). Ileal ring preparations from Wistar rats were pre-incubated in Ca2+-free KRB or with
each inhibitor for 20 min. Each ring was then contracted by KCl (50 mM). After the contraction had reached a plateau level, NO-
1886 (10 μM) was added to the incubation baths. Data are expressed as meansSD for 4-7 intestinal rings in each group. *P0.01,
compared with vehicle group.
Fig. 3 The effect of NO-1886 on ACh-
induced contraction in rat colon and rec-
tum. The colonic and rectal ring prepara-
tions from Wistar rats were pre-incubated
with NO-1886 (10 μM), W7 (100 μM)
and/or ML-9 (30 μM) for 20 min prior to
the ACh (100 μM) -induced contraction.
Vehicle treatment was used as controls.
ACh-induced maximum contraction was
recorded for each ring preparation. Each
contractile value was standardized against
the contraction level induced by 50 mM
KCl in the absence of pretreatment (1st
KCl). Data are expressed as meansSD
for 4-11 intestinal rings in each group. *P
0.01, compared with each vehicle group.
P0.01, compared with vehicle group
without inhibitor treatment.
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OLETF, a rat model of obesity associated with glu-
cose intolerance
To examine whether obesity or diabetes affects
intestinal contraction, spontaneous obese, type-2 dia-
betic OLETF rats (26, 27) were used in the subse-
quent experiments. The clinical and biochemical
characteristics of the OLETF and LETO control rats
are summarized in Table 1. OLETF rats at 17 weeks
of age had higher body weight, visceral fat mass
and plasma triglyceride concentration compared to
LETO control rats. Blood glucose levels in the fed
condition were also higher in the OLETF rats than
in the LETO rats. However, fasting levels of blood
glucose and plasma total cholesterol were not sig-
nificantly different from those in LETO rats. Oral
glucose tolerance tests revealed that the blood glu-
cose levels of OLETF rats were increased markedly
after the oral glucose load (2 g/kg), indicating that
this model animal decreased glucose disposal from
the circulation (glucose intolerance). The glucose
intolerance state observed in our OLETF rats would
be attributed to the insulin resistance of the tissues
as had been demonstrated by a hyperinsulinemic
glucose clamp study (26). The OLETF rats were
therefore used in this study as a model for assess-
ing the effect of obesity-related metabolic disorders
on intestinal contraction.
OLETF rats showed increased ACh receptor expres-
sion and ACh-induced contraction in the intestine
ACh-induced cholinergic signaling is mediated by
muscarinic ACh receptors, which regulate intestinal
tone under physiological conditions (28). As shown
in Fig. 4A, the colon ring preparations of the OLETF
rats had increased levels of muscarinic M3 ACh
receptor (ACh-M3R) protein, one of the major ACh
receptors expressed in the intestine. The expres-
sion levels for myosin light chain (MLC) protein in
the colon were, however, not significantly different
between the OLETF and LETO rats (Fig. 4B).
A
B
Fig. 4 The protein expression levels of muscarinic M3 ACh
receptor (ACh-M3R ; A) and myosin light chain (MLC ; B) in
the colon of OLETF and LETO rats. The intensities of the im-
munoreactive bands were quantified by scanning densitometry
and expressed as arbitrary units (the ordinate axis). The mean
values in the LETO group were designated as 1.0. Data are ex-
pressed as meansSD for 4 rats in each group. *P0.01, com-
pared with LETO group.
Table 1. Physical and biochemical characteristics of the LETO
and OLETF rats
LETO OLETF
Body weight (g) 402.718.8 508.337.6*
Fat mass (g)
Epididymal 5.50.9 12.60.4
Retroperitoneal 5.70.7 17.93.1
Mesenteric 3.40.4 8.01.6
Blood glucose (mg/dl)
Fed 1013.6 134.523.2*
Fasting 77.78.6 80.36.0
[After glucose load (2g/kg)]
30 min 137.714.6 279.739.1
60 min 131.37.5 297.39.5
120 min 102.316.8 13846.8
Plasma triglyceride (mg/dl) 47.721.6 133.221.9
Plasma Total cholesterol (mg/dl) 60.87.6 72.27.0
Data are meansSD. *p0.05, p0.01 vs. LETO rats.
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We next examined whether elevated ACh-M3R
protein expression affected ACh-induced contrac-
tion in colon ring preparations of OLETF rats. It
should be noted that the ACh-induced contraction
of the intestinal rings isolated from normal LETO
rats (Fig. 5) were lower than those isolated from the
Wistar rats (Fig. 3). Since LETO rats at 17 weeks
of age were used in the experiments for Fig. 5
(Wistar rats aging 7-9 weeks were used in the ex-
periments for Fig. 3), observed low contraction
in the LETO ring preparations might involve the
effect of the aging, or of the difference in rat strain.
However, we could not clearly show the relation-
ships between these factors and intestinal contrac-
tion in the present study. In our experiments with
the Long-Evans rat strain, ACh (100 μM) -induced
colonic contraction was significantly higher in
the OLETF rats than in the LETO rats (open bar)
(Fig. 5).
NO-1886 attenuated ACh-induced excessive con-
traction of the colon of OLETF rats
To examine the effects of NO-1886 on colonic
contraction in OLETF and LETO rats, colon ring
preparations from both rat groups were treated with
or without NO-1886 for 20 min prior to ACh (100
μM) -induced contractions. ACh-induced contrac-
tion was attenuated significantly by pretreatment
with NO-1886 in both rat groups (closed bars in
Fig. 5). It should be noted that ACh-induced con-
tractile levels of OLETF colons were decreased by
NO-1886 pretreatment to normal levels seen in the
LETO colons without NO-1886 treatment (compare
closed bar of OLETF rat group with open bar of
LETO rat group in Fig. 5).
DISCUSSION
NO-1886 belongs to the class of lipoprotein lipase
activators that have beneficial effects on abnormal
lipid metabolism observed in diabetic or obese con-
ditions (14, 15). Many studies on the use of NO-
1886 have therefore suggested that this drug may
become an effective agent for treating hyperlipide-
mia, diabetes and obesity (13-15). However, the cel-
lular and molecular mechanisms of these improve-
ments remain to be clarified. Furthermore, only a
few reports have demonstrated the direct effects
of NO-1886 on the intracellular signaling pathways
(17). Therefore, investigating the effect of NO-1886
on cellular functions responsible for the regulation
of nutrient metabolism as well as other pathophysi-
ological conditions has the potential to reveal more
details of the pharmacological properties of this
drug.
In this paper we show that NO-1886 attenuated
KCl- and/or ACh-induced contraction in rat intes-
tines. The inhibitory effect of NO-1886 on excess
contraction of smooth muscle cells was first dem-
onstrated in vascular smooth muscle cells of rats
(17). In the vasculature, NO-1886 inhibited KCl-
induced or α1-adrenergic receptor-mediated con-
tractions (17). Although the precise mechanisms
underlying NO-1886-induced inhibition of smooth
muscle contractions remain unclear, it is possible
the mechanism may involve Ca2+ influx-dependent
contractile components in the vascular smooth mus-
cle cells (17). Inhibition of MLCK, an enzyme in-
volved in the final step of the contractile mecha-
nisms of smooth muscle cells (29), abolished NO-
1886-induced vasorelaxation (17), indicating that
NO-1886 attenuates smooth muscle contraction via
an extracellular Ca2+, and an MLCK-dependent path-
way. As extracellular Ca2+ and MLCK also partici-
pate in gastrointestinal smooth muscle contractile
mechanisms (18), we examined the effect of a Ca2+-
free environment or inhibitors of signaling molecules
including MLCK, on the action of NO-1886. The
lack of extracellular Ca2+ or inhibition of MLCK by
ML-9 blocked the relaxing effect of NO-1886 in the
intestines similar to that observed in vascular smooth
Fig. 5 ACh- induced contraction of colonic ring prepara-
tions of the OLETF and the LETO rats. The colon ring prepara-
tions from both rat groups were treated with or without NO-
1886 (10 μM) for 20 min prior to the ACh (100 μM)-induced con-
traction. Each contractile value was standardized against the con-
traction level induced by 50 mM KCl in the absence of pretreat-
ment (1st KCl). Data are expressed as meansSD for 4 rats in
each group. * P0.01, compared with vehicle group. P0.01,
compared with LETO (vehicle) group.
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muscle cells. We therefore concluded that NO-1886
had the ability to attenuate contractions in both in-
testinal and aortic smooth muscle cells.
Gastrointestinal motility, including contraction of
intestinal smooth muscle cells, regulates intestinal
transit of nutrients, thereby affecting their diges-
tion and absorption (12). In this regard, it has been
shown that rapid intestinal transit may result in re-
duced rates of absorption, whereas delayed transit
accelerates the rate, leading to accumulation of ex-
cess nutrients in the body (12). However, while in-
creased intestinal absorption of nutrients has been
suggested to occur in obesity (30), intestinal tran-
sit rate itself, may not be altered in this condition
(30, 31). Previous in vivo studies have demonstrated
that NO-1886 decreased accumulation of excess nu-
trients including blood glucose, lipids and also re-
duced body fat mass (15, 16). These facts suggest
that NO-1886 would not have adverse effects on nu-
trient metabolism even if it had an inhibitory effect
on intestinal contraction.
It is well established that abnormal intestinal mo-
tility is associated with various digestive diseases
such as irritable bowel syndrome and gastrointes-
tinal symptoms including constipation, diarrhea and
bloating (8-10). Some reports have described these
alterations in intestinal motility being induced by
stressed conditions or by metabolic syndromes in-
cluding diabetes and obesity (1, 2, 12). Shinbori, et
al. (11) demonstrated that ileal ring preparations
from STZ-induced diabetic rats had hyper-contractile
ability, while Xing and Chen speculated that colonic
motility may be altered in obese patients (12). The
concept that NO-1886 may be applicable for treat-
ment of metabolic disturbances including obesity
and diabetes prompted us to examine, 1) whether
obesity-based metabolic complications actually al-
ter intestinal contractility, and 2) whether NO-1886
affected intestinal contractility under such condi-
tions.
In this study we used OLETF rats as a model of
metabolic disturbances associated with severe obe-
sity (26, 27). The OLETF rats at 17 weeks of age
used in the study had visceral fat obesity and higher
plasma triacylglycerol concentrations compared with
normal control (LETO) rats. Blood glucose levels
in the fed condition were also higher in the OLETF
rats than in the LETO rats, although these levels
were still within the normal range (Table 1). Blood
glucose levels did not increase significantly in the
OLETF rats until after oral loading of a large amount
of glucose, suggesting that this rat model rat at 17
weeks of age had visceral obesity and glucose in-
tolerance (or insulin resistance), but did not yet
show hyperglycemia under sedentary conditions.
To examine the effect of obesity on intestinal con-
tractility, ACh-induced contractile force was meas-
ured using colonic ring preparations isolated from
OLETF and LETO rats. ACh receptor-mediated hy-
percontractility has been reported in intestinal strips
from type I diabetic rats (11), a finding that im-
plies a relationship between blood glucose levels
and intestinal motility. Although the OLETF rats
used in our study did not have excessive hypergly-
cemia, as seen in type I diabetic rats (11), ACh-
induced contraction of the colon was actually in-
creased compared with control LETO rats. In addi-
tion, we showed the protein levels of ACh-M3R were
elevated in the colon of the OLETF rats.
Two ACh receptor subtypes, namely ACh-M2 re-
ceptor (ACh-M2R) and ACh-M3R are expressed in
intestinal smooth muscles (25). M3-receptors stimu-
late intestinal smooth muscle contraction by elevat-
ing intracellular Ca2+, while M2 receptors induce
contraction indirectly by inhibiting the production
of cyclic AMP (25). Despite the predominance of
M2-receptors, direct contraction of intestinal and
bladder smooth muscle is mediated by the M3-
receptor subtype, and only this subtype is involved
in contraction in vitro (25). Shinbori, et al. (11) re-
ported that mRNA levels of ACh-M3R, but not ACh-
M2R, were increased in the ileum of type I diabetic
rats. On the other hand, Carrier and Aronstam (32)
demonstrated that muscarinic responsiveness, but
not muscarinic receptor content, was increased in
ileal smooth muscle in the same strain of diabetic
rats. Only a few reports had described intestinal ex-
pression levels of each ACh receptor in the obese
condition. In our study we found that colonic con-
tractions were increased in the obese condition with
insulin resistance and that this impairment was pos-
sibly due to an elevation of ACh-M3R in smooth
muscle cells. Further studies are needed to clarify
the mechanisms underlying obesity-induced altera-
tions in intestinal ACh receptor expression.
Our results showed that pretreatment with NO-
1886 attenuated ACh-induced colonic hypercontrac-
tility in OLETF rats to normal levels seen in the
LETO rat colon preparations. These results indicate
that NO-1886 improves obesity-induced colonic hy-
percontractility, in addition to its beneficial effects on
metabolic abnormalities (14-16). However, in the
present study this inhibitory effect of NO-1886 on
excessive contraction was assessed only in vitro us-
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ing intestinal ring preparations. Therefore, whether
or not NO-1886 has similar effects in vivo was not
determined in this study.
In summary, we demonstrated that NO-1886 at-
tenuated KCl- and ACh-induced contraction in rat in-
testines. This effect of NO-1886 was dose-dependent
and required extracellular Ca2+ and intracellular
MLCK. NO-1886 also attenuated excess intestinal
contraction caused by obesity in combination with
insulin resistance. Future work involving oral ad-
ministration of NO-1886 to animals would reveal
the more direct effects of this drug on altering in-
testinal motility associated with metabolic abnor-
malities.
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